ClinicalTrials.gg
Not yet recruitingNCT04286373ESNV-SPAUpdated Apr 27, 2025

Efficacy of Non-invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies

An interventional study of active stimulation then placebo stimulation and placebo stimulation then active stimulation in Axial Spondyloarthritis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Planned enrollment
20th of 30
120 · median 188
Started
2025
with 2 others
No phase
13 of 40
6 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
24th of 40
by date
Lead sponsor
7 of 40
Assistance Publique - Hôpitaux de Paris

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 20th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 24th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

The primary objective of the study is to study the change in SpA disease activity, according to ASAS20 definition (Anderson et al., 2001), after 8 weeks of VNS treatment versus placebo non-specific stimulation (control group).

The secondary objectives of the Clinical Investigation are to show differences in disease evolution between the active and placebo periods of 8 weeks treatment with active VNS versus placebo VNS of the following items:

  1. Change in disease activity according to "ASAS40" criteria
  2. Obtaining a partial remission according to the ASAS definition
  3. Change in BASFI
  4. Change in C-reactive protein (CRP)serum level and erythrocytes sedimentation rate (ESR),
  5. Change in ASDAS_CRP and ASDAS_ESR
  6. Difference in levels of circulating cytokines, IL-6, IL-23, IL-17, IL-33 and of matrix metallopeptidases (MMP3-8-9).
  7. Change in quality of life : assessment according to the following indexes: SF-36, AS Quality of Life (ASQOL)
  8. Change in Health Index of patient with SpA (ASAS HI) and of the Productivity at Work Index (WPI)
  9. Change in fatigue (BASDAI 1st question) and global pain
  10. Change in Anxiety and Depression Assessment (HAD)
  11. Change in BASMI
  12. Change in non-steroidal anti-inflammatory drugs (NSAID) intake score.
Read the detailed description

This multi-center study will be conducted in rheumatology departments of 14 public hospitals in France.

The study is part of the SMART-VNS (TM) project: a Structured Multidisciplinary Program for Advanced Research on the Therapeutic effects of Vagus Nerve Stimulation in inflammatory, infectious, neurological and painful diseases.

After informed consent, patients will be included in the Clinical Investigation by rheumatologists during routine consultations. Included patients will be randomised in two groups differing by the sequence in which the treatments are to be administered: Group A: VNS active for 8 weeks, then VNS placebo for 8 weeks; and Group B: VNS placebo for 8 weeks then VNS active for 8 weeks. In order to maintain the blind, investigators administering the stimulation will be different from those evaluating the patients, and the latter will be blinded to the treatment administered. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ will be used in this Clinical Investigation during the active VNS periods. The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA). During the placebo VNS periods, VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Frangos et al., 2015, Fang et al., 2017). All randomized patients will be followed up until the end of their stimulation periods. Data collection for the assessment of endpoints will be performed by biochemistry tests and questionnaires in all patients at the first and the last visit of each period.

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • axial spondyloarthritis
  • vagus nerve stimulation
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient from 18 to 90 years with axial SpA, meeting the ASAS classification criteria, followed for at least one year, with presence of radiological sacro-illitis (ankylosing spondylitis) or not;
  • Patient suffering active SpA, with or without treatment, having a total BASDAI score ≥ 4 (0-10) at baseline and a score of global pain ≥ 4 (0-10);
  • SpA insufficiently relieved despite optimal drug management for at least 6 months including at least 2 different NSAIDs at the maximum tolerated dose for at least 3 months (or less in case of intolerance) and at least two lines of biotherapies or discontinued SpA treatments due to intolerance, .

Exclusion criteria

Exclusion Criteria:

  • Patient under guardianship;
  • Cardiac arrhythmia;
  • Patients with cochlear implant;
  • Patients with known heart disease;
  • Hypotension;
  • Asthmatic patients;
  • Refusal to participate in the study or to sign the ;
  • Pregnant or breastfeed woman;
  • No affiliation to a social security scheme;
  • Previous VNS treatment;
  • Incapacity to attend the weekly appointment during the study period;
  • 12- Head trauma with fracture of rock. In case of skin lesions of the left ear, recruitment will be delayed until these lesions are healed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A: active stimulation then placebo stimulation

    VNS active stimulation: Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks, then VNS placebo for 8 weeks. The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period. The VNS placebo stimulation period being the control one.

    Device: active stimulation then placebo stimulation

  • Experimental
    Group B: placebo stimulation then active stimulation

    VNS placebo for 8 weeks, then VNS active stimulation Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks. The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period. The VNS placebo stimulation period being the control one.

    Device: placebo stimulation then active stimulation

Interventions

  • Deviceactive stimulation then placebo stimulation

    The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation. VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015). The two stimulation periods will be separated by a 4 weeks wash-out period.

  • Deviceplacebo stimulation then active stimulation

    VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015). The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation. The two stimulation periods will be separated by a 4 weeks wash-out period.

06

What researchers measure

Primary outcomes

  1. Change according to the ASAS Response Criteria (ASAS 20)

    Assessement of efficacy of VNS treatment: for SpA patients under VNS treatment and under placebo non-specific stimulation, to demonstrate improvement of VNS treatment, according to ASAS20 definition, greater than placebo non-specific stimulation. ASAS20 Response is defined as follows: an improvement of 20% compared to baseline and an absolute improvement from baseline of at least 1 unit, in 3 of the 4 ASAS domains: as well as no baseline deterioration of 20% and of at least one unit in the fourth domain.

    Time frame: At baseline and week 12

Secondary outcomes

  1. Improvement according to "ASAS40" criteria

    A 40% improvement "ASAS40" after VNS treatment

    Time frame: at baseline, 3 months, 4 months ans 7 months

  2. Partial remission

    Partial remission according to the ASAS definition

    Time frame: at baseline, 3 months, 4 months ans 7 months

  3. Improvement of BASFI

    Time frame: at baseline, 3 months, 4 months ans 7 months

  4. Serum CRP level

    Changes of C-reactive protein (CRP) serum level

    Time frame: at baseline, 3 months, 4 months ans 7 months

  5. Serum ESR

    Changes of serum erythrocytes sedimentation rate (ESR)

    Time frame: at baseline, 3 months, 4 months ans 7 months

  6. ASDAS_CRP

    Changes of ASDAS_CRP

    Time frame: at baseline, 3 months, 4 months ans 7 months

  7. ASDAS_ESR

    Changes of ASDAS_ESR

    Time frame: at baseline, 3 months, 4 months ans 7 months

  8. Circulating cytokines level of IL-6, IL-17, IL-23, IL-33, and MMP-3-8-9

    Difference in levels of circulating cytokines: IL-6, IL-23,IL-17, IL-33 and of matrix metallopeptidases (MMP3-8-9)

    Time frame: at baseline, 3 months, 4 months ans 7 months

  9. Quality of life: SF-36

    Assessement of quality of life: according to the following indexes: SF-36

    Time frame: at baseline, 3 months, 4 months ans 7 months

  10. Quality of life: AS Quality of Life (ASQOL)

    Assessement of quality of life: according to the AS Quality of Life (ASQOL).

    Time frame: at baseline, 3 months, 4 months ans 7 months

  11. ASAS-HI

    Change of Health Index of patient with SpA (ASAS HI)

    Time frame: at baseline, 3 months, 4 months ans 7 months

  12. WPI Productivity Index

    Change of Health Index of patient with the WPI Productivity Index

    Time frame: at baseline, 3 months, 4 months ans 7 months

  13. Fatigue severity evaluation

    A visual analogue scale (VAS) will be used to evaluate fatigue severity

    Time frame: at baseline, 3 months, 4 months ans 7 months

  14. Global Pain assessment

    Global Pain assessment will be used.

    Time frame: at baseline, 3 months, 4 months ans 7 months

  15. Anxiety and Depression Assessment

    Anxiety and Depression Assessment : HAD

    Time frame: at baseline, 3 months, 4 months ans 7 months

  16. BASMI

    Time frame: at baseline, 3 months, 4 months ans 7 months

  17. Non-steroidal anti-inflammatory drugs (NSAID) intake score

    Change of non-steroidal anti-inflammatory drugs (NSAID) intake score

    Time frame: at baseline, 3 months, 4 months ans 7 months

07

Study locations

1 site
  • Neurophysiology and Neuromodulation Unit, Department of Physiology, Raymond Poincaré Hospital, APHP
    Garches, Hauts-de-seine 92380, France
08

References and documents

Publications

  • Azabou E, Bao G, Costantino F, Jacota M, Lazizi C, Nkam L, Rottman M, Roux AL, Chevallier S, Grimaldi L, Breban M. Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol. Front Hum Neurosci. 2021 Jun 30;15:679775. doi: 10.3389/fnhum.2021.679775. eCollection 2021. PubMed 34276328 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 15 months is below that.

Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Feb 27, 2020
StartEst.
Sep 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04286373
Responsible party
Sponsor
First posted
Feb 27, 2020
Start date
Sep 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 27, 2025

Study contacts

Eric AZABOU, MD, PhD
Contact
eric.azabou@aphp.fr
+ 33 1 47 10 79 40
Eric AZABOU, MD, PhD
principal investigator · Neurophysiology and Neuromodulation Unit, Department of Physiology, Raymond Poincaré Hospital, APHP
Maxime Breban, MD, PhD
study director · Department of Rheumatology, Ambroise Paré Hospital, APHP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion